

Hikma remains a constituent of the FTSE4Good Index

London, 16 July 2025 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it remains a constituent of the FTSE4Good Index Series, affirming its strong environmental, social and governance practices.

The FTSE4Good Index Series was created by the global index and data provider FTSE Russell to highlight companies that demonstrate good sustainability practices and to support investors that wish to align their portfolios with such organisations.

Hikma has been a member of the FTSE4Good Index since 2014. Throughout this period, Hikma has made significant progress by embedding sustainability into its corporate strategy and reinforcing its commitment to providing access to high-quality generic medicines, with 262 million patients treated globally in 2024.

Placing access to medicines at the heart of our purpose, Hikma empowers its people, protects the environment, and acts with unwavering integrity.

Tim Brooks, VP Sustainability for Hikma, commented, “We are pleased to remain constituents of the FTSE4Good, recognising our ongoing commitment to ensure access to high-quality medicines across our regions in North America, Europe, and MENA. Enabling access to essential medicines is our top priority, underpinning our efforts to promote more sustainable business practices and aligning with our purpose of putting better health within reach, every day.”

For more information on how Hikma acts responsibly, including details of the targets Hikma has set, visit our website <https://www.hikma.com/acting-responsibly/> and read our 2024 Sustainability Report <https://www.hikma.com/responsibility/sustainability-reports/>

- ENDS -



Enquiries

Investors

Susan Ringdal +44 (0)20 7399 2760/ +44 7776 477050
EVP, Strategic Planning and Global Affairs

Guy Featherstone +44 (0)20 3892 4389/ +44 7795 896738
Director, Investor Relations

FTI Consulting (media)

Ciara Martin 44 (0)7779 775979
schikma@fticonsulting.com

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB/stable S&P and BBB/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com